A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/16/2006	CA2607044A1 Cardiovascular disease therapies
11/16/2006	CA2607014A1 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
11/16/2006	CA2606890A1 Immunogens for meningitidis-a vaccines
11/16/2006	CA2606887A1 Pharmaceutical composition
11/16/2006	CA2606880A1 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
11/16/2006	CA2606875A1 Pharmaceutical combination including an antibiotic and an active ingredient selected among carveol, thymol, carvacrol, alpha-ionone and beta-ionone
11/16/2006	CA2606847A1 Antibacterial agents
11/16/2006	CA2606783A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
11/16/2006	CA2606778A1 Vascular disease therapies
11/16/2006	CA2606598A1 Pharmaceutical formulations of hdac inhibitors
11/16/2006	CA2606535A1 Delivery of tigecycline in the presence of warfarin
11/16/2006	CA2606507A1 Polymorphic forms of (s)- tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate
11/16/2006	CA2606390A1 Stable lyophilized anthracycline glycosides
11/16/2006	CA2606254A1 .beta.-amino acid derivatives
11/16/2006	CA2605341A1 Modified-release pharmaceutical compositions
11/16/2006	CA2604624A1 Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
11/16/2006	CA2604600A1 Pregabalin free of isobutylglutaric acid and a process for preparation thereof
11/16/2006	CA2604052A1 Methods and compositions for the treatment of cns-related conditions
11/16/2006	CA2603445A1 Anticancer combination therapy using sunitinib malate
11/16/2006	CA2602535A1 Substituted beta-lactams and their use in medicine
11/16/2006	CA2586250A1 Compositions for treating respiratory viral infections and their use
11/15/2006	EP1722227A2 Epitopes formed by non-covalent association of conjugates
11/15/2006	EP1721987A1 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
11/15/2006	EP1721984A2 Method for cloning and expression of the NheI restriction endonuclease in E. coli
11/15/2006	EP1721979A1 Compositions and methods for increasing bone mineralisation
11/15/2006	EP1721906A1 3-pyridinium methylcephem compound
11/15/2006	EP1721905A1 Thiazole derivative
11/15/2006	EP1721904A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
11/15/2006	EP1721903A1 Compositions and therapeutic methods involving isoflavones and analogues thereof
11/15/2006	EP1721902A1 Production methods of thiazoline compounds and optically active alpha-alkylcysteine
11/15/2006	EP1721901A1 Abc transporter inhibitor
11/15/2006	EP1721898A1 Quinoline and pyridoquinoxaline derivatives as antibacterial agents
11/15/2006	EP1721897A1 Phenylpyridinylpiperazin derivatives, the process to make them and the pharmaceutical compositions containing them
11/15/2006	EP1721896A1 Phenylpyridinylpiperazin derivatives, the process to make them and the compositions containing them
11/15/2006	EP1721889A1 Process for the preparation of phenethylamine derivatives
11/15/2006	EP1721625A2 Biodegradable medical devices with enhanced mechanical strength and pharmacological functions
11/15/2006	EP1721614A1 Epirubicine hydrochloride for treating hepatitis C virus
11/15/2006	EP1721613A1 Hesperidin for the treatment of epilepsy, migraine, schizophrenia, depression and drug abuse
11/15/2006	EP1721612A2 Immunemodulating oligosaccharides
11/15/2006	EP1721611A1 Nutritional supplement with oligosaccharides for a category of HIV patients
11/15/2006	EP1721610A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
11/15/2006	EP1721609A2 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases
11/15/2006	EP1721608A2 Upregulation of type III endothelial cell nitric oxide synthase by HMG-CoA reductase inhibitors
11/15/2006	EP1721607A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
11/15/2006	EP1721606A2 Buffered compositions for dialysis
11/15/2006	EP1721604A1 Stable capsule preparation
11/15/2006	EP1721602A1 Controlled release oral drug delivery system
11/15/2006	EP1721601A1 Use of taurine for enhancing lipid synthesis in the epidermis
11/15/2006	EP1721158A2 Modulators of angiogenesis
11/15/2006	EP1721157A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions
11/15/2006	EP1720994A1 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
11/15/2006	EP1720985A2 Polypeptide participating in pyridoxine biosynthesis, a polynucleotide coding the polypeptide and those uses
11/15/2006	EP1720891A1 Crystalline forms of a pharmaceutical compound
11/15/2006	EP1720890A2 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
11/15/2006	EP1720889A1 Sulfated oligosaccharide derivatives
11/15/2006	EP1720886A1 Macrolides and methods for producing same
11/15/2006	EP1720885A1 A process for making olanzapine in a polymorph form i
11/15/2006	EP1720884A1 Pharmacologically acceptable salts of clopidogrel
11/15/2006	EP1720883A1 Pyrazolotriazines as kinase inhibitors
11/15/2006	EP1720882A2 Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
11/15/2006	EP1720881A1 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
11/15/2006	EP1720880A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4]benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs thereof as well as related compounds for the treatment of proliferative diseases
11/15/2006	EP1720878A1 Heteroaryl-fused pyrazolo derivatives
11/15/2006	EP1720877A2 Aryl substituted purine analogues
11/15/2006	EP1720876A1 Crystalline forms of valacyclovir hydrochloride
11/15/2006	EP1720875A1 8- [3-amino-piperidin-1-yl]-xanthines, the production thereof, and the use of the same as medicaments
11/15/2006	EP1720874A1 4-substituted piperidine derivatives
11/15/2006	EP1720872A1 Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
11/15/2006	EP1720871A1 3,5-disubstituted 1h-pyrrolo [2,3-b] pyridines as jnk inhibitors
11/15/2006	EP1720870A1 Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
11/15/2006	EP1720868A1 Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain
11/15/2006	EP1720867A2 Process for the preparation of ziprasidone
11/15/2006	EP1720864A1 Benzimidazol substituted thiophene derivatives with activity on ikk3
11/15/2006	EP1720863A2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
11/15/2006	EP1720862A1 Kinase inhibitors
11/15/2006	EP1720860A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists
11/15/2006	EP1720859A2 Chemokine receptor antagonists
11/15/2006	EP1720858A1 Crystal forms of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino -quinazolin-6-yl}-allyl)-acetamide
11/15/2006	EP1720857A1 Dihydropyridinone derivatives
11/15/2006	EP1720856A2 Hiv integrase inhibitors
11/15/2006	EP1720854A1 Phthalzinone derivatives as pde4 inhibitors
11/15/2006	EP1720853A1 Novel polymorphic form of imatinib mesylate and a process for its preparation
11/15/2006	EP1720850A1 Coumarin derivative and use thereof
11/15/2006	EP1720849A1 Pyranone derivatives useful for treating cancer
11/15/2006	EP1720848A1 Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
11/15/2006	EP1720847A1 Histamine-3 receptor modulators
11/15/2006	EP1720846A1 Use of thiadiazole urea derivatives
11/15/2006	EP1720845A1 Isothiourea derivatives
11/15/2006	EP1720844A2 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
11/15/2006	EP1720843A2 Process for the preparation of substituted triazole compounds
11/15/2006	EP1720841A2 Quinazoline derivatives and therapeutic use thereof
11/15/2006	EP1720839A1 Pyridazinones as antagonists of a4 integrins
11/15/2006	EP1720837A1 Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
11/15/2006	EP1720836A1 6-substituted 2,3,4,5-tetrahydro-1h-benzo [d]azepines as 5-ht2c receptor agonists
11/15/2006	EP1720835A1 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
11/15/2006	EP1720826A2 Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
11/15/2006	EP1720825A1 New compounds, methods for their preparation and use thereof
11/15/2006	EP1720613A2 Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
11/15/2006	EP1720612A2 Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
11/15/2006	EP1720610A1 Alcohol metabolism moderating composition

1 ... 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 ... 7860